Related Experiment Video
Updated: Jul 27, 2026
08:35
Complete Thymectomy in Adult Rats with Non-invasive Endotracheal Intubation
Published on: December 29, 2014
One hundred consecutive thymectomies for myasthenia gravis
F C Detterbeck1, W W Scott, J F Howard
1Department of Surgery, University of North Carolina School of Medicine, Chapel Hill, USA.
The Annals of Thoracic Surgery
|July 1, 1996
Summary
This study on thymectomy for myasthenia gravis found minimal complications and significant patient improvement. A programmatic approach to sternotomy thymectomy benefits patients across the disease severity spectrum.
Area of Science:
- Neurosurgery
- Immunology
- Thoracic Surgery
Background:
- 100 thymectomies for myasthenia gravis performed between June 1997 and November 1993.
- Study conducted at University of North Carolina Hospitals.
Purpose of the Study:
- Evaluate the efficacy and safety of a standardized thymectomy protocol for myasthenia gravis.
- Assess outcomes including morbidity, mortality, and long-term disease improvement.
Main Methods:
- Consistent preoperative, intraoperative, and postoperative care protocol.
- Median sternotomy approach with complete thymus and perithymic fat removal.
- Systematic data collection on patient outcomes and follow-up.
Main Results:
- No perioperative mortality or long-term morbidity observed.
- Mean postoperative hospital stay of 6.3 days; 96% extubated on day of surgery.
- 78% of patients showed improvement; 69% of mild and 29% of severe cases achieved pharmacologic remission.
Conclusions:
- Programmatic sternotomy thymectomy demonstrates minimal morbidity and mortality.
- The procedure is beneficial for myasthenia gravis patients of varying age and disease severity.
- Standardized care protocols enhance thymectomy outcomes for myasthenia gravis.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:28Disorders of the Skeletal Muscle
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...